Is Ozempic Killing Liposuction? A Stock That Could Get Hit Hard From New Weight-Loss Drugs
Portfolio Pulse from Aaron Bry
Novo Nordisk's diabetes drug, Ozempic, is gaining popularity for weight loss, potentially impacting companies providing weight-loss services like liposuction and bariatric surgeries. Johnson & Johnson reported a shortfall in its Q3 medical device sales due to a decrease in bariatric surgeries, which could be linked to the rise of Ozempic. Eli Lilly is preparing to release its own weight loss drug, Mounjaro, to compete with Ozempic and Wegovy.
October 27, 2023 | 7:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Johnson & Johnson's Q3 medical device sales fell short due to a decrease in bariatric surgeries, potentially linked to the rise of Ozempic.
The rise of Ozempic as a weight loss drug could lead to a decrease in the demand for bariatric surgeries, impacting Johnson & Johnson's medical device sales.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Eli Lilly is preparing to release its own weight loss drug, Mounjaro, to compete with Ozempic and Wegovy.
The release of Mounjaro could potentially increase Eli Lilly's market share in the weight loss drug market.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 70
POSITIVE IMPACT
Novo Nordisk's Ozempic is gaining popularity as a weight loss drug, which could increase the company's revenues.
The popularity of Ozempic as a weight loss drug could lead to increased sales and revenues for Novo Nordisk.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100